9-Jan-2026
No press releases found.
Biopharma stocks to see increased M&A activity amid Eli Lilly-Ventyx deal
Seeking Alpha News (Thu, 8-Jan 1:15 PM ET)
Market Chameleon (Thu, 20-Nov 6:51 AM ET)
XBI Bullish Call Spread is Undervalued at $4.25
Market Chameleon (Tue, 9-Apr 7:04 AM ET)
The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the Index ). The S&P Biotechnology Select Industry represents the biotechnology segment of the S&P Total Market Index ( S&P TMI ). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted.
State Street SPDR S&P Biotech ETF trades on the ARCA stock market under the symbol XBI.
As of January 9, 2026, XBI stock price climbed to $124.50 with 8,901,303 million shares trading.
XBI has a beta of 0.90, meaning it tends to be less sensitive to market movements. XBI has a correlation of 0.38 to the broad based SPY ETF.
XBI has a market cap of $8.69 billion. This is considered a Mid Cap stock.
In the last 3 years, XBI traded as high as $129.12 and as low as $63.80.
XBI has outperformed the market in the last year with a return of +35.4%, while the SPY ETF gained +19.0%. In the last 3 month period, XBI beat the market returning +18.5%, while SPY returned +3.4%. However, in the most recent 2 weeks XBI has underperformed the stock market by returning -1.4%, while SPY returned +0.5%.
XBI support price is $122.02 and resistance is $125.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XBI shares will trade within this expected range on the day.